Navigation Links
Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week
Date:1/31/2011

BEVERLY HILLS, Calif., Jan. 31, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX™ joint health formula, launched commercially in December 2010.  Specifically, the study found that reduction of pain was statistically significant after as little as one week of ERGOFLEX use.  Similar improvements were seen with range of motion.  Benefits continued during the six weeks subjects took ERGOFLEX, and for some the benefits persisted during the subsequent six-week washout period.

ERGOFLEX is the only joint health complex containing the powerful antioxidant L-Ergothioneine (ERGO) and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health. It is the first in a series of products built around the ERGO platform that are planned by OXIS.  

"These powerful and statistically significant final results strongly suggest that ERGOFLEX can provide significant quick and lasting relief from mild-to-moderate joint pain while improving range of motion, which results in an improved quality of life," said Bernie Landes, President of OXIS International.  "These clinically demonstrated results represent an important breakthrough for those tens of millions of Americans who suffer with chronic joint pain and diminished range of motion.  While most joint pain products only address the symptoms, ERGOFLEX targets and relieves oxidative stress, which frequently is the underlying cause of joint ailments. It also provides a suite of extensively researched natural ingredients that help maintain the structural integrity of joints and relieve pain."

The study included 12 subjects ta
'/>"/>

SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... 2011 Covance Inc. (NYSE: CVD ) today ... Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
... IRVINE, Calif., Feb. 22, 2011 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and twelve ... Endologix President and Chief Executive Officer, said, "We made tremendous ... quarter of 2010.  Revenue grew by 41% over the corresponding ...
Cached Medicine Technology:Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 3Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 4Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 5Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 6Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 7Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 8Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 9Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 10
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... the student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 ... This is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Aug. 3 Blue Cross and Blue Shield of Georgia ... administration of the H1N1 (swine flu) vaccine when it becomes ... be covered for members whose benefit plans provide coverage for ... coverage of seasonal flu vaccine administration for those whose health ...
... A new class of antibody drugs may provide a powerful ... but specialists need to be alert for the possibility of ... Journal of AAPOS (American Association for Pediatric Ophthalmology ... of Santa Barbara, Calif., discusses issues related to the use ...
... of synthetic biology will, in the medium term, open up ... with engineering principles. This will facilitate the development, not only ... new materials. Early-stage dialogue with the public on the natural ... success and acceptance of this new technology. With a joint ...
... 3 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast: , , ... When: Friday, August 14, 2009 at 12:00 PM ET, ... Live over the Internet -- Simply log on to the web at the, ... Conference call dial-in phone numbers:, Toll-free from the US: ...
... , SILVER SPRING, Md., Aug. 3 Four ... session of ongoing couples therapy can greatly increase chances for ... The largest clinical trial with couples to date, it shows ... feedback technique were 46.2 percent less than that of couples ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) ... E. ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... and his extensive knowledge of PDL,s humanization technology will allow him ... seek to maximize the value of our antibody humanization patents and ...
Cached Medicine News:Health News:BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases 2Health News:Synthetic biology -- opportunities and risks 2Health News:Synthetic biology -- opportunities and risks 3Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
HME only...
Medicine Products: